Welcome back to Healthy Innovations! 👋

This week we're looking at one of the most quietly significant shifts happening in biotech right now – a new model for developing therapies for genetic diseases so rare that traditional drug development simply can't reach them. It starts with a baby, a six-month sprint, and a therapy that had never existed before. And it ends with a question the whole field is now trying to answer.

Let’s dive in!

The core problem in rare disease medicine is structural. Drug development works when you can spread the cost of a therapy across enough patients to justify building it. But of the roughly 10,000 known rare diseases, most affect so few people that no company can make the numbers work – so most never get a trial, an approval, or a treatment.

For most of those patients, the options are limited to managing symptoms and waiting.

What's emerging now is a genuinely different answer – one that doesn't try to fix the old model but replaces it. The idea is called N-of-1 medicine: therapies designed for a single person's specific genetic variant, built on shared platform technology that gets faster and cheaper to deploy with every new patient treated.

In February 2025, it stopped being theoretical.

KJ Muldoon was born in August 2024 at the Children's Hospital of Philadelphia (CHOP). Within 48 hours, his ammonia levels were critically elevated. Sequencing confirmed severe CPS1 deficiency – a urea cycle disorder with very high early mortality in neonatal-onset cases. His only established treatment option was a liver transplant. At five months old, he was too small and too unstable to receive one.

Two researchers at Penn Medicine, Rebecca Ahrens-Nicklas and Kiran Musunuru, had spent two years building a CRISPR-based platform for liver metabolic disorders. When KJ's results came back, they had the tools. What they needed was a therapy built specifically for his mutations.

They designed a base-editing therapy targeting his exact genetic variant – a form of gene editing that corrects a single DNA letter without cutting the double strand, reducing off-target risk. The therapy was packaged into lipid nanoparticles, the same delivery technology used in mRNA vaccines, and manufactured from scratch for one patient. According to reporting at the time, the FDA approved the expanded access application within approximately one week.

KJ received three infusions between February and April 2025. 307 days after admission, he went home. CHOP reported meaningfully improved ammonia control, better protein tolerance, and reduced dependence on medication – a significant clinical improvement, though not a cure.

By February 2026, he was walking and talking.

Watch KJ’s full story here:

KJ's outcome is significant. The architecture that produced it may matter more for the field.

The therapy wasn't invented from scratch. It was assembled from reusable components – the same delivery system, the same base-editing architecture – with one new element: a guide RNA sequence written specifically for KJ's variant. Most of the platform carries over. What changes per patient takes weeks to design, not years.

That's the key shift.

If a gene-editing platform is modular – same chassis, different guide sequence – the cost of building it doesn't restart with each new patient. It spreads. And the regulatory and manufacturing learnings from one program accelerate the next one.

The NIH's Bespoke Gene Therapy Consortium (BGTC), a partnership of more than 35 organizations including the FDA, has been formalizing exactly this logic since 2021. Its goal is a shared operational playbook – common manufacturing standards, master regulatory files, shared safety data – so any institution can build on the same foundation rather than reinventing it. The BGTC is focused on diseases where patient numbers make traditional development impossible. In the words of one of its directors, these are diseases with "literally no business model."

KJ's case is already informing a follow-on program designed to treat patients across seven different urea cycle gene disorders – using the same platform, adapted for each new variant.

The bottleneck right now is not scientific, it is manufacturing. Each bespoke therapy still demands custom synthesis, safety profiling, and single-patient-scale production. Until those steps are standardized and made accessible to far more institutions, this approach will remain concentrated in a small number of academic centers with the necessary infrastructure.

KJ's case also gave regulators something concrete to build policy around.

In November 2025, the FDA Commissioner and the head of the FDA's biologics division co-authored a piece in the New England Journal of Medicine proposing a new approval pathway for bespoke therapies. The argument: when a condition affects three patients worldwide, a randomized controlled trial isn't a realistic evidence bar. A clearly defined biological target, sound scientific rationale, safety data, and measurable clinical improvement should be enough.

By February 2026, the FDA had published draft guidance formalizing the framework – with KJ's physicians joining FDA leaders on stage at the agency's Rare Disease Day event to mark the moment.

Real questions remain – around legislative authority, how payers in the US and UK will handle therapies with no established pricing model, and whether reimbursement frameworks can move fast enough to keep pace with the science. Those aren't small problems. But the regulatory intent is now clear in a way it wasn't 18 months ago.

The BGTC's playbook is being tested across eight clinical programs, covering conditions including propionic acidemia, Barth syndrome, and Charcot-Marie-Tooth disease type 4J. The EMA is developing its own adaptive frameworks in Europe. Academic centers in the UK, France, and Germany are building similar rapid-development capabilities.

The science is moving. The harder work now is on the access side: how to fund therapies designed for one patient, approved through a new pathway, with no existing reimbursement model to plug them into. That will need new approaches from payers, governments, and industry that don't yet exist.

KJ Muldoon is proof the biology works. Getting it to the next patient – and the one after that – is the problem the field is now racing to solve.

🔐 GenMD. Healthcare data is one of the most valuable assets in medicine – and one of the hardest to share legally, safely, or quickly. GenMD is building synthetic digital twins of real medical datasets: HIPAA and GDPR-compliant replicas of electronic health records that behave statistically like the original data without exposing actual patients.

The platform covers structured and unstructured data alike – EHRs, claims, demographics, diagnoses, lab results, physician notes, and medical images. It uses differential privacy techniques to reduce re-identification risk, and is available as either a self-hosted deployment or a managed environment, with SOC 2 and FedRAMP-certified infrastructure underneath.

The core proposition is straightforward: health systems sit on datasets that could accelerate research, train better AI models, and unlock pharma partnerships – but privacy constraints make sharing them difficult and slow. GenMD positions itself as the layer between a hospital's private data and the outside world, making that data usable without directly exposing patients. For research teams, AI developers, and data commercialization efforts, that's a meaningful unlock.

🎨 Going to the gallery may be good medicine. A study from University College London, published in Innovation in Aging, has found that regular arts and cultural engagement – visiting galleries, reading, listening to music – is linked to slower biological aging at the DNA level. Researchers analyzed data from 3,556 UK adults, comparing their arts habits with epigenetic clock readings across seven measures of biological age and pace of aging.

People who engaged with arts at least weekly appeared to age around 4% more slowly than those who rarely did – a figure that held up after accounting for BMI, smoking, income, and education. The effect was comparable to regular exercise, and strongest in adults over 40. Engaging in a wider variety of activities showed even clearer benefits, with researchers suggesting each type of arts activity brings different cognitive, emotional, and social stimulation.

The lead researcher described it as the first evidence that arts engagement influences aging at a biological level. Which raises the question of whether your next museum membership should go on your health insurance claim.

Thank you for reading the Healthy Innovations newsletter!

Keep an eye out for next week’s issue, where I will highlight the healthcare innovations you need to know about.

Have a great week!

Alison ✨

P.S. Join over 900 healthcare leaders who get these insights delivered straight to their inbox! Healthy Innovations is read weekly by executives from AstraZeneca, GSK, Vertex, Roche, and leading academics, startup founders, agency teams, and investors. Subscribe now to stay ahead of industry trends!